GLP-1 Benefits Beyond Weight Loss

GLP-1 medications were first developed for type 2 diabetes and later approved for weight management. But a growing body of clinical trial evidence has supported additional approvals: sleep apnea, fatty liver disease, kidney disease progression in type 2 diabetes, and cardiovascular risk reduction. Here's a clear summary of what's approved versus what's still in research.

Approved indications beyond weight loss (as of 2026)

The following indications have received FDA approval based on large, randomised clinical trial evidence. Each approval applies to specific drugs in specific populations — not to all GLP-1 medications across all patients.

Each approved indication has its own evidence base and specific population criteria. The approval for one indication does not imply effectiveness for another — these are separately evaluated findings.

Cardiovascular risk reduction

The SELECT trial demonstrated that semaglutide (Wegovy) reduced major cardiovascular events — heart attack, stroke, and cardiovascular death — in adults with overweight or obesity and established cardiovascular disease, without type 2 diabetes. This was a landmark result and led to a specific FDA approval for cardiovascular risk reduction in this population.

Separately, semaglutide (Ozempic) had earlier demonstrated cardiovascular benefit in adults with type 2 diabetes in the SUSTAIN-6 trial. These are different trials, different populations, and different brand/dose contexts — even though the same molecule (semaglutide) is involved.

For a detailed overview of the cardiovascular evidence, see: GLP-1s and Heart Health.

Earlier-stage research areas

Beyond the approved indications, researchers are studying GLP-1 medications in a range of other conditions where the biological rationale is plausible:

• PCOS — early studies show metabolic improvements, but no large-scale randomised trial evidence yet. See: GLP-1s and PCOS.
• Alzheimer's disease and neurodegeneration — observational data and mechanistic research are encouraging, but large outcome trials are still ongoing as of 2026. No approval exists.
• Addiction and substance use — early observations from trial data and case reports suggest possible effects on reward-related behaviours. Research is very early.
• Non-alcoholic steatotic liver disease (MASLD) without fibrosis — broader liver health studies ongoing beyond the MASH-specific approval.

In each case, "early research" means the evidence is not yet sufficient for regulatory approval or clinical guidelines. Do not make treatment decisions based on early-stage findings.

What this means in practice

The expansion of GLP-1 indications reflects the breadth of metabolic conditions that share common underlying drivers — insulin resistance, obesity, inflammation. GLP-1 medications appear to address several of these drivers simultaneously.

But several important cautions apply:

• Each approval is drug-specific and population-specific — do not assume an approval for one drug applies to another
• Regulatory approvals are for specific indications with specific criteria — your eligibility depends on your individual health picture
• Evidence from trials in one population doesn't automatically extrapolate to another
• These medications require clinical oversight, prescription, and monitoring

If you have a condition listed here and are considering a GLP-1, the starting point is a conversation with your clinician — ideally one familiar with your specific condition.

Frequently asked questions

If I'm prescribed semaglutide for weight loss, does it also protect my heart?
The SELECT trial's cardiovascular finding applied to a specific population — adults with overweight/obesity and established cardiovascular disease without type 2 diabetes. Whether this applies to you depends on your individual health picture. Speak to your clinician.

Are all these indications available in every country?
Regulatory approvals differ by country. The approvals described here are FDA (US) approvals. Check with your local clinician or pharmacist for what's available where you live.

Does tirzepatide have all the same approvals as semaglutide?
No. Each drug has its own regulatory approval history. As of 2026, tirzepatide has approval for weight management and obstructive sleep apnea (in the US). Semaglutide has approvals for type 2 diabetes, weight management, cardiovascular risk reduction, MASH, and kidney disease progression.

I read that GLP-1s may help with dementia — is that true?
Research is ongoing, but there is no regulatory approval for dementia or Alzheimer's prevention as of 2026. Early findings are being studied in larger trials. Do not rely on a GLP-1 for cognitive benefits until evidence is clearer.